Aeglea BioTherapeutics In... (AGLE)
NASDAQ: AGLE
· Real-Time Price · USD
12.01
0.75 (6.66%)
At close: Nov 27, 2023, 10:00 PM
Aeglea BioTherapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | -886K | n/a | n/a | n/a | 688K | 198K | 168K | 174K | 625K | 1.36M | 3.64M | 1.4M | 13.7M | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | -886K | n/a | n/a | n/a | 688K | 198K | 168K | 174K | 625K | 1.36M | 3.64M | 1.4M | 13.7M | n/a |
Operating Income | -53.57M | -12.18M | -55.39M | -44.15M | -18.34M | -159.25M | -18.81M | -19.16M | -18.75M | -22.42M | -24.44M | -20.44M | -20.29M | -6.71M | -18.21M |
Interest Income | 6.49M | 19.29M | 5.18M | 5.92M | 1.25M | 350K | 420K | 410K | 288K | 104K | 35K | 34K | 36K | 19K | 22K |
Pretax Income | -44.79M | 67.67M | -69.01M | -38.84M | -40.1M | -217.07M | -18.46M | -18.78M | -18.44M | -22.31M | -24.44M | -20.42M | -20.28M | -6.74M | -18.22M |
Net Income | -44.77M | 67.59M | -69.03M | -38.84M | -40.11M | -217.08M | -18.42M | -18.82M | -18.23M | -22.32M | -24.44M | -20.45M | -20.31M | -6.83M | -18.22M |
Selling & General & Admin | 11.94M | 19.9M | 10.65M | 11.51M | 8.58M | 12.06M | 5.23M | 5.08M | 6.95M | 7.67M | 8.82M | 7.3M | 6.84M | 6.82M | 6.35M |
Research & Development | 41.62M | 106.97M | 44.74M | 32.64M | 24.66M | 17.39M | 13.78M | 14.25M | 11.98M | 15.37M | 16.98M | 16.78M | 14.85M | 13.58M | 11.86M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | -8K | -72K | -32K | 24K | 5K | -30K | -15K | -24K | -52K | -31K |
Operating Expenses | 53.57M | 126.87M | 55.39M | 44.15M | 33.24M | 29.45M | 19M | 19.33M | 18.93M | 23.05M | 25.8M | 24.09M | 21.69M | 20.4M | 18.21M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 410K | 288K | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 126.87M | n/a | n/a | 33.24M | 29.45M | 19M | 19.33M | 18.93M | 23.05M | 25.8M | 24.09M | 21.69M | 20.4M | 18.21M |
Income Tax Expense | 15K | -19K | -18K | n/a | -3K | 7K | -36K | 38K | -209K | 9K | -35K | 23K | 26K | 92K | -22K |
Shares Outstanding (Basic) | 346.05M | 374.39M | 50.89M | 27.59M | 4.29M | 3.82M | 3.77M | 3.82M | 3.77M | 3.29M | 2.64M | 2.64M | 2.63M | 2.63M | 2.62M |
Shares Outstanding (Diluted) | 346.05M | 374.39M | 50.89M | 27.59M | 4.29M | 3.82M | 3.77M | 3.82M | 3.77M | 3.29M | 2.64M | 2.64M | 2.63M | 2.63M | 2.62M |
EPS (Basic) | -0.13 | 0.18 | -1.36 | -1.41 | -9.34 | -56.79 | -4.89 | -4.93 | -4.84 | -6.79 | -9.26 | -7.75 | -7.72 | -2.6 | -6.94 |
EPS (Diluted) | -0.13 | 0.18 | -1.36 | -1.41 | -9.34 | -56.79 | -4.89 | -4.93 | -4.84 | -6.79 | -9.26 | -7.75 | -7.72 | -2.6 | -6.94 |
EBITDA | -53.57M | 66.65M | -55.39M | -44.15M | -18.34M | 160.48M | -18.81M | -18.78M | -18.35M | -22.05M | -24.04M | -20.03M | -19.88M | -6.31M | -17.85M |
EBIT | n/a | 18.88M | n/a | n/a | -18.34M | -159.25M | -18.88M | -18.37M | -18.16M | -22.42M | -24.44M | -20.44M | -20.29M | -6.71M | -18.21M |
Depreciation & Amortization | n/a | -924.41K | n/a | n/a | -39.59K | 580K | 384K | 385K | 401K | 378K | 403K | 411K | 412K | 398K | 355K |